Search research articles
Contact Us
Filters
Showing results (71-80 of 160) with videos related to
Page
of 16
Sort By:
The Journal of Membrane Biology
|
June 30, 1980
Alamethicin-induced conductances in lipid bilayers: I. Data analysis and simple steady-state model
M Fleischmann, C Gabrielli, M T Labram, et al.
Chemical Communications (Cambridge, England)
|
July 23, 2016
Facile synthesis of one-dimensional organometallic-organic hybrid polymers based on a diphosphorus complex and flexible bipyridyl linkers
M Elsayed Moussa, B Attenberger, E V Peresypkina, et al.
Clinical Rheumatology
|
July 10, 2014
Efficacy of golimumab plus methotrexate in methotrexate-naïve patients with severe active rheumatoid arthritis
Paul Emery, Roy M Fleischmann, Elizabeth C Hsia, et al.
Annales De Dermatologie Et De Venereologie
|
January 1, 1992
[Cutaneous Cytomegalovirus ulceration in AIDS: diagnosis by in situ hybridization and response to treatment]
M Fleischmann, B Milpied, B Dréno, et al.
The British Journal of Dermatology
|
April 1, 1992
Induction of myelo-monocytic My7 antigen (CD13) expression by interferon-alpha in basal cells of cutaneous T-cell lymphomas
B Dreno, M Fleischmann, S Valard, et al.
Archives of Dermatology
|
September 1, 1993
In vitro induction of basal keratinocyte MY7 antigen expression in cutaneous T-cell lymphoma is associated with response to interferon-alfa therapy
P Celerier, M Fleischmann, N Basset-Seguin, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
November 12, 2014
A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis
Roy M Fleischmann, Nemanja S Damjanov, Alan J Kivitz, et al.
Journal of Biological Response Modifiers
|
August 1, 1984
Discrimination between nonmalignant and malignant cells by combinations of IFN-gamma and IFN-alpha/beta
W R Fleischmann, R C Newton, C M Fleischmann, et al.
The Journal of Rheumatology
|
August 16, 2015
Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years
Ronald F van Vollenhoven, Roy M Fleischmann, Daniel E Furst, et al.
RMD Open
|
March 4, 2017
DAS28-CRP and DAS28-ESR cut-offs for high disease activity in rheumatoid arthritis are not interchangeable
Roy M Fleischmann, Désirée van der Heijde, Philip V Gardiner, et al.
Page
of 16
Search research articles
Search
Showing results (71-80 of 160) with videos related to
Sort By:
Page
of 16
The Journal of Membrane Biology
|
June 30, 1980
Alamethicin-induced conductances in lipid bilayers: I. Data analysis and simple steady-state model
M Fleischmann, C Gabrielli, M T Labram, et al.
Chemical Communications (Cambridge, England)
|
July 23, 2016
Facile synthesis of one-dimensional organometallic-organic hybrid polymers based on a diphosphorus complex and flexible bipyridyl linkers
M Elsayed Moussa, B Attenberger, E V Peresypkina, et al.
Clinical Rheumatology
|
July 10, 2014
Efficacy of golimumab plus methotrexate in methotrexate-naïve patients with severe active rheumatoid arthritis
Paul Emery, Roy M Fleischmann, Elizabeth C Hsia, et al.
Annales De Dermatologie Et De Venereologie
|
January 1, 1992
[Cutaneous Cytomegalovirus ulceration in AIDS: diagnosis by in situ hybridization and response to treatment]
M Fleischmann, B Milpied, B Dréno, et al.
The British Journal of Dermatology
|
April 1, 1992
Induction of myelo-monocytic My7 antigen (CD13) expression by interferon-alpha in basal cells of cutaneous T-cell lymphomas
B Dreno, M Fleischmann, S Valard, et al.
Archives of Dermatology
|
September 1, 1993
In vitro induction of basal keratinocyte MY7 antigen expression in cutaneous T-cell lymphoma is associated with response to interferon-alfa therapy
P Celerier, M Fleischmann, N Basset-Seguin, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
November 12, 2014
A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis
Roy M Fleischmann, Nemanja S Damjanov, Alan J Kivitz, et al.
Journal of Biological Response Modifiers
|
August 1, 1984
Discrimination between nonmalignant and malignant cells by combinations of IFN-gamma and IFN-alpha/beta
W R Fleischmann, R C Newton, C M Fleischmann, et al.
The Journal of Rheumatology
|
August 16, 2015
Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years
Ronald F van Vollenhoven, Roy M Fleischmann, Daniel E Furst, et al.
RMD Open
|
March 4, 2017
DAS28-CRP and DAS28-ESR cut-offs for high disease activity in rheumatoid arthritis are not interchangeable
Roy M Fleischmann, Désirée van der Heijde, Philip V Gardiner, et al.
Page
of 16